Eli Lilly & Co.(NYSE:LLY) shares had its target price raised by Goldman Sachs from $39.00 to $42.00 in a research note issued to investors on Sept. 14. The firm currently has a sell rating on the stock. Additionally, analysts expect that Eli Lilly & Co. will post $0.00 EPS for the current fiscal year. The company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
How Should Investors Trade LLY Now? Find Out - goo.gl/S9q6H